

## **Serina Therapeutics Announces Appointment of Mr. Mike Loya to Serina's Board of Directors**

Huntsville, AL, January 27, 2017

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology platform for drug development based upon polyoxazoline (POZ™), announced today that Mr. Mike Loya has been appointed to the Serina Board of Directors. Mr. Loya is currently President of Vitol, Inc., and director of the Vitol Group, a privately held energy and commodities company with over 40 offices worldwide. In 2015 Vitol had revenues in excess of \$ 165 billion USD and is currently the largest independent trader of energy products in the world with assets over \$ 35 billion USD.

“I am delighted to announce the appointment of Mr. Loya to the Serina Board of Directors,” said Dr. Moreadith. “Mr. Loya is part of the team that built Vitol into one of the truly great private companies worldwide. He brings tremendous depth and breadth of business acumen to our Board of Directors, and I look forward to working closely with him as Serina transitions into a clinical-stage development company with a rich pipeline of proprietary and partnered programs.”

“I am very excited to join the board of Serina Therapeutics. It is very special to me to have this opportunity to assist in the development of such transformational technology.”

Mr. Loya received his undergraduate degree in mechanical engineering at the University of Texas at El Paso, and a Master in Business Administration from Harvard University. Mike began his career at Vitol as a trader in 1992, and rapidly ascended to his current position in 1999. In his 25 year career, he has opened and expanded markets for Vitol in Europe, Africa and the Americas.

SER-214, a once-per-week subcutaneous administration of rotigotine delivered in a standard insulin syringe, is Serina's most advanced clinical candidate and is currently completing enrolment in a Phase I program in patients suffering from Parkinson's disease. Serina plans to advance SER-214 into Phase II development in 2017-2018.

In addition to advancing its pipeline programs in pain, oncology, refractory seizures and inflammatory diseases, Serina is currently collaborating with leading pharmaceutical companies to further unlock the promise of the POZ platform and is actively seeking new partnerships.

### **About Serina**

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that has developed novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products

for various pharmaceutical partners. POZ technology provides strong differential characteristics that may demonstrate improved clinical benefits versus PEG and other polymer-based technologies. Besides developing its own pipeline of pharmaceutical products for Parkinson's disease and cancer, Serina has partnered its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit [www.serinatherapeutics.com](http://www.serinatherapeutics.com).